Wellbeing in the teachers\u27 profession. Theoretical considerations and multi-cultural research in Europe

The article commences by introducing the “Teaching to Be” project, an initiative under the European Policy Experimentation, which focuses on supporting teachers’ professional growth and wellbeing in the realm of social and emotional learning. Subsequently, it delves into a presentation of various well-being models and approaches to professional wellbeing. This highlights the diversity of theoretical perspectives within this domain, some of which harmonize with each other while others diverge. Simultaneously, it conscientiously acknowledges blind spots and proposes potential novel, alternative pathways for the future. The article serves as a prelude to fundamental deliberations that have notably influenced the “Teaching to Be” project as well as our future-oriented considerations. In this project, there is a dedicated focus on the well-being of teachers in their profession. (DIPF/Orig.

N-{2-Methyl-5-[(5-oxo-10,11-dihydro-5H-dibenzo[a,d]cyclo­hepten-2-yl)amino]­phen­yl}benzamide

In the title compound, C29H24N2O2, the two aromatic rings of the tricyclic unit are oriented at a dihedral angle of 32.27 (8)°. In the crystal N—H⋯O hydrogen bonds link the mol­ecules into chains along the a axis. Further N—H⋯·O inter­actions link the chains

CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing

BACKGROUND: Chimeric antigen receptor (CAR)-based T cell therapy is in early clinical trials to target the neuroectodermal tumor, neuroblastoma. No preclinical or clinical efficacy data are available for retinoblastoma to date. Whereas unilateral intraocular retinoblastoma is cured by enucleation of the eye, infiltration of the optic nerve indicates potential diffuse scattering and tumor spread leading to a major therapeutic challenge. CAR-T cell therapy could improve the currently limited therapeutic strategies for metastasized retinoblastoma by simultaneously killing both primary tumor and metastasizing malignant cells and by reducing chemotherapy-related late effects. METHODS: CD171 and GD2 expression was flow cytometrically analyzed in 11 retinoblastoma cell lines. CD171 expression and T cell infiltration (CD3+) was immunohistochemically assessed in retrospectively collected primary retinoblastomas. The efficacy of CAR-T cells targeting the CD171 and GD2 tumor-associated antigens was preclinically tested against three antigen-expressing retinoblastoma cell lines. CAR-T cell activation and exhaustion were assessed by cytokine release assays and flow cytometric detection of cell surface markers, and killing ability was assessed in cytotoxic assays. CAR constructs harboring different extracellular spacer lengths (short/long) and intracellular co-stimulatory domains (CD28/4-1BB) were compared to select the most potent constructs. RESULTS: All retinoblastoma cell lines investigated expressed CD171 and GD2. CD171 was expressed in 15/30 primary retinoblastomas. Retinoblastoma cell encounter strongly activated both CD171-specific and GD2-specific CAR-T cells. Targeting either CD171 or GD2 effectively killed all retinoblastoma cell lines examined. Similar activation and killing ability for either target was achieved by all CAR constructs irrespective of the length of the extracellular spacers and the co-stimulatory domain. Cell lines differentially lost tumor antigen expression upon CAR-T cell encounter, with CD171 being completely lost by all tested cell lines and GD2 further down-regulated in cell lines expressing low GD2 levels before CAR-T cell challenge. Alternating the CAR-T cell target in sequential challenges enhanced retinoblastoma cell killing. CONCLUSION: Both CD171 and GD2 are effective targets on human retinoblastoma cell lines, and CAR-T cell therapy is highly effective against retinoblastoma in vitro. Targeting of two different antigens by sequential CAR-T cell applications enhanced tumor cell killing and preempted tumor antigen loss in preclinical testing

Tumor-Derived Extracellular Vesicles Impair CD171-Specific CD4+ CAR T Cell Efficacy

Chimeric antigen receptor (CAR) T cell efficacy against solid tumors is currently limited by several immune escape mechanisms, which may include tumor-derived extracellular vesicles. Advanced neuroblastoma is an aggressive childhood tumor without curative treatment options for most relapsed patients today. We here evaluated the role of tumor-derived extracellular vesicles on the efficacy of CAR T cells targeting the neuroblastoma-specific antigen, CD171. For this purpose, CAR T cell activation, cytokine production, exhaustion, and tumor cell-directed cytotoxicity upon co-culture was evaluated. Tumor-derived extracellular vesicles isolated from SH-SY5Y neuroblastoma cells neither affected CAR T cell activation nor expression of inhibitory markers. Importantly, exposure of CD4+ CD171-specific CAR T cells to tumor-derived extracellular vesicles significantly impaired tumor cytotoxicity of CAR T cells. This effect was independent of neurotrophic receptor tyrosine kinases 1 or 2 (NTRK1, NTRK2) expression, which is known to impact immune responses against neuroblastoma. Our results demonstrate for the first time the impact of tumor-derived extracellular vesicles and non-cell-mediated tumor-suppressive effects on CD4+ CAR T cell efficacy in a preclinical setting. We conclude that these factors should be considered for any CAR T cell-based therapy to make CAR T cell therapy successful against solid tumors

Detailed scanning probe microscopy tip models determined from simultaneous atom-resolved AFM and STM studies of the TiO2(110) surface

Enevoldsen GH, Pinto HP, Foster AS, et al. Detailed scanning probe microscopy tip models determined from simultaneous atom-resolved AFM and STM studies of the TiO2(110) surface. Physical Review B. 2008;78(4):045416.The atomic-scale contrast in noncontact atomic force microscopy (nc-AFM) images is determined by the geometry and exact atomic structure of the tip apex. However, the tip state is an experimentally unknown parameter, and the lack of insight into the tip apex often limits the possibilities of extracting precise quantitative and qualitative atomistic information on the surface under inspection. From an interplay between simultaneously recorded nc-AFM and scanning tunneling microscopy (STM) data, and atomistic STM simulations based on multiple scattering theory, we demonstrate how the state of the scanning probe microscopy (SPM) tip in the experiments may be determined. The analysis of a large number of experimental SPM images recorded with different tips reveals that no general correlation exists between the contrast observed in the nc-AFM and the tunneling current (I-t) images on TiO2(110) surface. The exact state of the SPM tip must, therefore, be determined for each specific case, which is normally a very difficult endeavor. However, our analysis of the AFM contrast on TiO2(110) surface allows us to considerably reduce the number of tips to be considered in a full simulation. By carefully evaluating the contrast of a handpicked library of SPM tips, we manage to determine a very accurate model of the SPM tip used in an experiment for the first time. It is envisioned that the approach presented here may eventually be used in future studies to screen for and select a SPM tip with a special functionalization prior to imaging an unknown sample, and in that way facilitate precise modeling and chemical identification of surface species